NasdaqGM:ATAIPharmaceuticals
Is AtaiBeckley (ATAI) A Bargain On Eli Lilly’s Takeover Deal?
Eli Lilly and Company has agreed to acquire AtaiBeckley (NasdaqGM:ATAI) in a cash and Contingent Value Right deal valued at up to $3.8b, putting fresh attention on the stock and its mental health pipeline.
See our latest analysis for AtaiBeckley.
AtaiBeckley’s merger announcement comes after a sharp move in the share price, with a 30-day share price return of 74.88% and year-to-date share price return of 85.27%. The 3-year total shareholder return of 251.47% highlights how sentiment around...